/11/05 4239-61854-01 451259 E-104-1999/2-US-15; E-104-1999/2-US-19

PATENT

Attorney Reference Number 4239-61854-01

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of: Pastan et al.

**Application No. 10/031,158** 

Filed: January 11, 2002 Confirmation No. 8170

For: T-CELL RECEPTOR Y ALTERNATE

READING FRAME PROTEIN, (TARP)

AND USES THEREOF

**Examiner:** Stephen L. Rawlings, Ph.D.

Art Unit: 1641

Attorney Reference No. 4239-61854-01

COMMISSIONER FOR PATENTS P.O. BOX 1450 ALEXANDRIA, VA 22313-1450 CERTIFICATE OF MAILING

I hereby certify that this paper and the documents referred to as being attached or enclosed herewith are being deposited with the United States Postal Service as First Class Mail in an envelope addressed to: COMMISSIONER FOR PATENTS, P.O. BOX 1450, ALEXANDRIA, VA 22313-1450 on the

date shown below.

Attorney or Agent for Applicant(s)\_\_\_

Date Mailed November 14, 2005

## TRANSMITTAL LETTER

Enclosed for filing in the application referenced above are the following:

Copy of Notice to Comply dated November 4, 2005

Sequence Listing

Computer Readable Copy

Paper Copy (identical to computer copy), 9 pages

Statement in compliance with 37 C.F.R. § 1.821 verifying identity of computer-

readable and paper copies

Amendment Accompanying Sequence Listing

The Director is hereby authorized to charge any additional fees that may be required, or credit over-payment, to Deposit Account No. 02-4550. A copy of this sheet is enclosed. Please return the enclosed postcard to confirm that the items listed above have been received.

Respectfully submitted,

KLARQUIST SPARKMAN, LLP

One World Trade Center, Suite 1600

121 S.W. Salmon Street Portland, Oregon 97204 Telephone: (503) 595-5300

Facsimile: (503) 595-5301

Susan Alpert Siegel, Ph.D.

Registration No. 43,121

10	SIPE	
Ni(	V 1 6 2005	١
ATT.	11. 1 <b>()</b> 2003	/
135	PADEMARKO	

## **Notice to Comply**

Application No.	Applicant(s)
10/031,158	PASTAN ET AL.
Examiner	Art Unit
Stephen L. Rawlings, Ph.D.	1643

## NOTICE TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS CONTAINING NUCLEOTIDE SEQUENCE AND/OR AMINO ACID SEQUENCE DISCLOSURES

Applicant must file the items indicated below within the time period set the Office action to which the Notice is attack	hed to
avoid abandonment under 35 U.S.C. § 133 (extensions of time may be obtained under the provisions of 37 CFR 1.	136(a)).

The for	e nucleotide and/or amino acid sequence disclosure contained in this application does not comply with the requirements such a disclosure as set forth in 37 C.F.R. 1.821 - 1.825 for the following reason(s):
	1. This application clearly fails to comply with the requirements of 37 C.F.R. 1.821-1.825. Applicant's attention is directed to the final rulemaking notice published at 55 FR 18230 (May 1, 1990), and 1114 OG 29 (May 15, 1990). If the effective filing date is on or after July 1, 1998, see the final rulemaking notice published at 63 FR 29620 (June 1, 1998) and 1211 OG 82 (June 23, 1998).
	2. This application does not contain, as a separate part of the disclosure on paper copy, a "Sequence Listing" as required by 37 C.F.R. 1.821(c).
	3. A copy of the "Sequence Listing" in computer readable form has not been submitted as required by 37 C.F.R. 1.821(e).
⊠	4. A copy of the "Sequence Listing" in computer readable form has been submitted. However, the content of the computer readable form does not comply with the requirements of 37 C.F.R. 1.822 and/or 1.823, as indicated on the attached copy of the marked -up "Raw Sequence Listing."
	5. The computer readable form that has been filed with this application has been found to be damaged and/or unreadable as indicated on the attached CRF Diskette Problem Report. A Substitute computer readable form must be submitted as required by 37 C.F.R. 1.825(d).
	6. The paper copy of the "Sequence Listing" is not the same as the computer readable from of the "Sequence Listing" as required by 37 C.F.R. 1.821(e).
	7. Other:
Ap	oplicant Must Provide:  An initial or substitute computer readable form (CRF) copy of the "Sequence Listing".
	An initial or substitute paper copy of the "Sequence Listing", as well as an amendment directing its entry into the ecification.
⊠ no	A statement that the content of the paper and computer readable copies are the same and, where applicable, include new matter, as required by 37 C.F.R. 1.821(e) or 1.821(f) or 1.821(g) or 1.825(b) or 1.825(d).

For questions regarding compliance to these requirements, please contact:

For Rules Interpretation, call (703) 308-4216

For CRF Submission Help, call (703) 308-4212

Patentin Software Program Support

Technical Assistance......703-287-0200

To Purchase Patentin Software......703-306-2600



PLEASE RETURN A COPY OF THIS NOTICE WITH YOUR REPLY